REFERENCES
1. Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542-56.
3. Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol 2015;21:3223-31.
4. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.
5. Meijnikman AS, Davids M, Herrema H, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med 2022;28:2100-6.
6. Sanal MG. The blind men ‘see’ the elephant-the many faces of fatty liver disease. World J Gastroenterol 2008;14:831-44.
7. Kagansky N, Levy S, Keter D, et al. Non-alcoholic fatty liver disease - a common and benign finding in octogenarian patients. Liver Int 2004;24:588-94.
8. Solon-Biet SM, McMahon AC, Ballard JW, et al. The ratio of macronutrients, not caloric intake, dictates cardiometabolic health, aging, and longevity in ad libitum-fed mice. Cell Metab 2014;19:418-30.
10. The Hill. Statue of revolutionary war general comes down in albany because he enslaved people. Available from: https://thehill.com/homenews/4067139-statue-of-revolutionary-war-general-comes-down-in-albany-because-he-enslaved-people/. [Last accessed on 23 Nov 2024].
11. Alryalat SA, Rawashdeh K, El khatib O, et al. The change from an eponym to a representative name: wegener to granulomatosis with polyangiitis. Sci Metri 2018;117:2077-89.
13. Ducati RG, Ruffino-Netto A, Basso LA, Santos DS. The resumption of consumption - a review on tuberculosis. Mem Inst Oswaldo Cruz 2006;101:697-714.
14. Mohan V, Seedat YK, Pradeepa R. The rising burden of diabetes and hypertension in southeast asian and african regions: need for effective strategies for prevention and control in primary health care settings. Int J Hypertens 2013;2013:409083.
15. Sanal MG. Is the change from NAFLD to MASLD driven by political correctness? J Hepatol 2024;80:e74-6.
16. Fouad Y, Ghazinyan H, Alboraie M, et al. Joint position statement from the Middle East and North Africa and sub-Saharan Africa on continuing to endorse the MAFLD definition. J Hepatol 2024;80:e194-7.
17. Miao L, Ye S, Zheng MH; Global Chinese Fatty Liver Collaborative, Global Obesity Collaborative. “Fatty” or “steatotic”: position statement from a linguistic perspective by the Chinese-speaking community. J Hepatol 2024;Online ahead of print.
18. Wu T, Ye J, Mo S, et al. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians. J Gastroenterol Hepatol 2024;39:1636-47.
19. Ramírez-Mejía MM, Jiménez-Gutiérrez C, Eslam M, George J, Méndez-Sánchez N. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification? Hepatol Int 2024;18:168-78.
20. Huang CF, Yeh ML, Dai CY, Huang JF, Chuang WL, Yu ML. Chronic hepatitis C related steatotic liver disease is more than “miscellaneous steatotic liver disease”. Clin Gastroenterol Hepatol 2024;22:2137-39.e2.
21. Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol 2015;21:3223-31.
22. Lee MH, Chen YT, Huang YH, et al. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. Clin Gastroenterol Hepatol 2024;22:1275-85.e2.
23. Liu CJ, Seto WK, Yu ML. Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD. Hepatol Int 2024;18:897-908.
24. Lima-Cabello E, García-Mediavilla MV, Miquilena-Colina ME, et al. Enhanced expression of pro-inflammatory mediators and liver X-receptor-regulated lipogenic genes in non-alcoholic fatty liver disease and hepatitis C. Clin Sci 2011;120:239-50.
25. Ciardullo S, Perseghin G. From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction. Metab Target Organ Damage 2024;4:30.
26. Machado MV. What should we advise MAFLD patients to eat and drink? Metab Target Organ Damage 2021;1:9.
27. Lai J, Wang HL, Zhang X, Wang H, Liu X. Pathologic diagnosis of nonalcoholic fatty liver disease. Arch Pathol Lab Med 2022;146:940-6.
28. Zhao Q, Deng Y. Comparison of mortality outcomes in individuals with MASLD and/or MAFLD. J Hepatol 2024;80:e62-4.
29. Alboraie M, Butt AS, Piscoya A, et al. Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in metabolic dysfunction-associated liver diseases. Med Sci Monit 2024;30:e945198.
30. Pan Z, Derbala M, AlNaamani K, Ghazinian H, Fan JG, Eslam M. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease. Ann Hepatol 2024;29:101512.
31. Pan Z, Al-Busafi SA, Abdulla M, Fouad Y, Sebastiani G, Eslam M. MAFLD identifies patients with significant hepatic fibrosis better than MASLD. Hepatol Int 2024;18:964-72.
